Skip to main content
Assets
Gilead Sciences logo
GILD.NASDAQ
Gilead Sciences
Health Care · Biotechnology

Biopharmaceutical company discovering, developing, and commercializing innovative medicines in areas of unmet medical need.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Gilead Sciences.

Historical AI Opinions

Gilead Sciences, Inc. (GILD.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ResearcherAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Neutral

5-Year Return Est.

+48.4%

Includes 1.58% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.45.0180.47115.94151.41186.87Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$132+3.9%Not Generated this time
$137+7.3%Not Generated this time
$142+11.0%Not Generated this time
$146+14.6%Not Generated this time
$151+18.4%Not Generated this time
$156+22.0%Not Generated this time
$160+25.5%Not Generated this time
$165+29.8%Not Generated this time
$170+33.4%Not Generated this time
$175+37.3%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

The most reasonable thesis projects Gilead as a 'steady compounder' rather than a hyper-growth stock. Lenacapavir will indeed be a commercial success, cementing Gilead's dominance in HIV and providing a durable revenue bridge beyond the Biktarvy patent expirations. However, the oncology division is likely to show mixed results: solid but moderate growth for Trodelvy, offset by continued headwinds in the cell therapy space. The company will remain a cash-generation machine, prioritizing dividend growth and share buybacks which support a high floor for the stock price. At the current level of $127.51, much of the immediate 'breakout' potential is priced in. Future returns will likely come from earnings growth (6-8% CAGR) and yield, driving the stock steadily higher toward $165-$175 by 2030 without severe multiple expansion.

2. Scenarios & Signals

2.1. Bull Case

In the bull case, the successful launch of Lenacapavir (Sunlenca) for PrEP fundamentally transforms the HIV landscape, capturing over 80% of the prevention market and significantly extending the longevity of the HIV franchise well into the late 2030s, effectively neutralizing concerns over the Biktarvy patent cliff. Concurrently, the oncology portfolio overcomes initial commercial hurdles; Trodelvy becomes the standard of care in multiple solid tumor indications (breast, bladder, lung), and the cell therapy division (Kite) revitalizes growth through manufacturing efficiencies and expansion into earlier lines of therapy. Strategic M&A adds a high-growth asset in inflammation or metabolic disease. Margins expand as the product mix shifts towards high-value long-acting injectables. The market re-rates GILD to a growth multiple (P/E 20x+), driving the stock toward $190-$200.

2.2. Bear Case

The bear case posits that the current valuation of ~$127 reflects peak optimism for Lenacapavir that may not fully materialize due to payer resistance, slow uptake of injectables, or aggressive competition from ViiV's Cabenuva. Meanwhile, the oncology pivot falters; Cell Therapy revenue continues to decline due to competition from bispecific antibodies and logistical complexities, while Trodelvy faces stiff competition from Enhertu and other ADCs. The looming Inflation Reduction Act (IRA) price negotiations targeting Biktarvy compress margins faster than anticipated. If the diversification strategy fails to offset legacy HIV erosion, the stock could mean-revert significantly, shedding the 'Lenacapavir premium' and falling back to the $90-$100 range as it returns to being viewed as a low-growth value trap.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 2,726Thinking Tokens: 1,090Response Tokens: 7,391Total Tokens: 11,207
Researcher modeSearch enabled · not used

This run was configured as Researcher, but no external search activity was recorded. The model proceeded from the supplied context as sufficient, effectively following a Thinker-style workflow.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced System Instruction Driven Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.